Upload
vlad
View
36
Download
0
Embed Size (px)
DESCRIPTION
Obstructive Sleep Apnea Medical Treatment including nPAP. A. Valipour, MD, FCCP Department of Respiratory and Critical Care Medicine Otto-Wagner-Hospital Vienna. Prevalence: ~2-4% of population Risk Factors: Obesity Male Gender Anatomic Risk Factors - PowerPoint PPT Presentation
Citation preview
Obstructive Sleep ApneaMedical Treatment
including nPAP
A. Valipour, MD, FCCPDepartment of Respiratory and Critical Care
MedicineOtto-Wagner-HospitalVienna
• Prevalence: ~2-4% of population• Risk Factors:
• Obesity • Male Gender• Anatomic Risk Factors
• Symptoms: • Excessive Sleepiness• Snoring/Apneas/Choking• Cognitive Dysfunction/Depression
• Cardiovascular and metabolic morbidity and mortality
Obstructive Sleep Apnea: Fact Sheet
OSA: Medical Treatment
• Weight Loss• Positional Therapy• Drugs• Nasal dilators• nPAP• Alternatives?
Peppard PE, JAMA 2000
10% weight gain predicts 32% increase
in AHI
10% weight loss predicts 26% decrease
in AHI
Peppard PE, JAMA 2000
Berger G, Eur Respir J 2009
• 160 untreated Patients with Sleep Apnea • Age 50 ± 11yr• BMI 29 ± 5 kg/m2
• AHI 23 ± 22/hr
• Follow-Up Polysomnographic Recordings (5 ± 3 yrs)
Berger G, Eur Respir J 2009
Baseline vs. Follow-Up
15% Improvement
46% Stable
39% Deterioriation
Berger G, Eur Respir J 2009
Δ BMI 1kg/m2/yr↓
Δ AHI 5/hr
Positional therapy can yield moderate reductions in AHI but is clearly inferior to CPAP and long term compliance is poor.
Predictors of response: young age, lower AHI, less obese
Treatment: Positional Therapy
ERS Task Force „Non-CPAP therapies in Sleep Apnoea“, ERJ in press 2010
Antidepressants → suppression of REM sleep → increasing airway toneAcetazolamide → metabolic acidosis → resp. drive ↑Theophylline → respiratory drive ↑Doxapram → respiratory drive ↑
NO EVIDENCE THAT ANY DRUG IS LIKELY TO BENEFIT IN PATIENTS WITH OSA
Treatment: Drugs
ERS Task Force „Non-CPAP therapies in Sleep Apnoea“, ERJ in press 2010
Principle: Nasal dilation → Nasal resistance ↓→ fraction of oral ventilation ↓
Evidence: No consistent effect → snoring → apneas → sleep architecture
Treatment: Nasal Dilators
ERS Task Force „Non-CPAP therapies in Sleep Apnoea“, ERJ in press 2010
Treatment: Positive Airway Pressure Therapy
Pneumatic Splint of Upper Airway
Positive Airway Pressure Therapy:
Schwab RJ, AJRCCM 1996
CPAP↓
„Normalization“ of
upper airway dimensions
Positive Airway Pressure Therapy:
Schwab RJ, AJRCCM 1996
Indications for CPAP treatment
• AHI > 30/hr regardless of symptoms
• AHI 5-30/hr with symptoms, e.g.
• Excessive daytime sleepiness
• Insomnia
• Impaired cognition
• Cardiovascular disease
Loube DI, Chest 1999
Cassel W, Eur Respir J 1996
Becker HF, Circulation 2003
Dernaika TA, J Clin Sleep Med 2009
Drager LF, Am J Respir Crit Care Med 2007
Marin J et al., Lancet 2005
CPAP-Treatment: Reduction in cardiovascular morbidity and
mortality
CPAP use in a clinical setting
• Compliance/Adherence
• Side effects
• Humidification
• Auto-CPAP
• Expiratory pressure relief
Pépin JL et al, AJRCCM 1999
Kingshott RN, AJRCCM 2000
McArdle N et al, AJRCCM 1999
Regular use within first three months predicts long-term use
Sucena M, Eur Respir J 2006
Gay P, Sleep 2006
Up to 30% refuse or stop CPAP
therapy due to side effects
Mask problems
Nasal intolerance
Noise of the machine
Claustrophobia
CPAP: Side effects
Massie CA, Chest 1999
Potential strategies aimed at improving compliance and
decreasing side effects• Education and training
• Local therapy (Nose, Full Face Mask,…..)
• Humidification
• Auto-CPAP
• Expiratory Pressure Relief
Massie CA, CHEST 1999
Nussbaumer Y, Chest 2006
86% preferred Auto-CPAP over fixed CPAP
Ayas NT, SLEEP 2004;27:249-53.
CPAP vs. Auto-CPAP: no change in hours of use
Patruno V, Chest 2007
CPAP: Expiratory pressure relief
Nilius G, Chest 2006
No difference in compliance
after 7 weeks of treatment
EPR-PAP
Less side effects to the upper airways
↓ Need for humidification ↓
Potential benefit for Expiratory Pressure Relief PAP
Valipour A, ERS 2008
EPR-PAP
Pts. with symptomatic OSA requiring CPAP
Need for humidification?
CPAP
Need for humidification?
24 months 24 months
Matching: age, sex, BMI, OSA severity, sleepiness, CPAP pressure
Retrospective review of medical and insurance reports
3 sleep labs
Valipour A, ERS 2008
05
101520253035
CPAP EPR-PAP
% patients with humidifier prescription
p = 0.02
Valipour A, ERS 2008
37% reduction in humidifier prescription
with EPR-PAP
Alternatives to treat OSA with CPAP?
• High flow transnasal insufflation
(TNI)
• Expiratory nasal valves
• „Didgeridoo“
10L/min - 20L/minHigh Flow
Insufflation
„High Flow“ Transnasal Insufflation (TNI)
TNI creates positive pharyngeal pressure
McGinley BM, Am J Respir Crit Care Med 2007
McGinley BM, Am J Respir Crit Care Med 2007
Responders:
Upper Airway Resistance Syndrome
Sleep-Hypopnea-SyndromeMild OSAS
Nilius G, Chest 2009
Expiratory Nasal Valves
Nasal valve treatment:Expiratory resistance creates positive upper
airway pressure
Colrain IM, J Clin Sleep Med 2008
1. Weight reduction: first line
treatment
2. Drugs inefficient
3. Nasal dilators inefficient
Conclusions
1. CPAP: Gold standard treatment
2. Side-Effects:
Humidification: Auto-CPAP, EPR-PAP
3. TNI, Nasal Valves → mild OSA
Conclusions
Aim: Keep the upper airway open
Thank you for your attention
Positive airway pressure alternatives?
Puhan MA, British Medical Journal 2006
Puhan MA, British Medical Journal 2006
• Obesity (Visceral Fat)
• Male Gender
• Menopause
• Age
OSA: Clinical Risk Factors
Pathophysiology: mechanical upper airway obstructionPharygeal pressure < Atmospheric Pressure
Flow
SaO2
Thorax
Abdomen
Apnea Apnea
OSA: Polygraphic Recording
OSA: Pathophysiological Consequences
• Repetitive Hypoxia
• Intrathoracic Pressure Swings
• Sleep Fragmentation
• Hypersomnolence/Insomnia• Fatigue/Depression
• Traffic accidents/Work accidents
• Art. Hypertension• Arrythmias• Myocardial infarction, Stroke• Metabolic Consequences
OSA: Clinical Consequences
Nilius G, Chest 2006
Ayas NT, SLEEP 2004;27:249-53.
Auto-CPAP: Reduction in mean therapeutic pressure
Ayas NT, SLEEP 2004;27:249-53.
CPAP vs. Auto-CPAP: no difference in AHI
Patruno V, Chest 2007
Mador MJ, CHEST 2005
No significant difference in complianceNo significant difference in symptoms (ESS)
Solutions ?
Problems Noise and bulk Nasal intolerance
Mask related problems
Technologic improvement
Limitation of the leaks around the
mask
Nasal decongestants
Full Face Mask
Warm humidifier +++
Limitation of mouth leaks (mouth strap)
Good education
Adapted mask
Technologic improvement
Trained technician
Modified from Levy P, ERS Course 2005
Auto-CPAPEPR-PAP
Young T, AJRCCM 2002
Prevalence of OSA
Lee RWW, Sleep 2009
• Retrognathia
• Neck Size
• Tongue Size
• Uvula
• Tonsills
OSA: Anatomic Risk Factors
Diagnosis: Recording of Sleep and Breathing
New England J Medicine 1999
Goncalvez SC, Chest 2007
Parish JM, Chest 2009
Punjabi NM, PLOS Med 2009